Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis

I. Y. Ossiisky (Vinnitsa, Ukraine)

Source: Annual Congress 2004 - Problems of resistances in tuberculosis
Session: Problems of resistances in tuberculosis
Session type: Thematic Poster Session
Number: 3979
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Y. Ossiisky (Vinnitsa, Ukraine). Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis. Eur Respir J 2004; 24: Suppl. 48, 3979

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB.
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008

Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT)
Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis
Year: 2008


Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR)
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004

Express diagnostics of mycobacterium tuberculosis (MBT) drug resistance at disseminated tuberculosis (DT)
Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives
Year: 2008

Recurrence after successful treatment of pulmonary tuberculosis (TB) with multidrug-resistance (MDR)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008


In vitro activity of triclosan ( TCN ) and thiolactomycin ( TLM ) against multi-drug-resistant ( MDR ) strains of mycobacterium tuberculosis ( M. tb )
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB
Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities
Year: 2005


Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009


Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB)
Source: Eur Respir J 2005; 26: Suppl. 49, 199s
Year: 2005

The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M)
Source: Eur Respir J 2004; 24: Suppl. 48, 52s
Year: 2004

Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004

Diagnostic value of PCR-RT for the detection of DNA Mycobacterium tuberculosis complex (MBT) in blood from patient with pulmonary tuberculosis (PT)
Source: Annual Congress 2009 - Diagnostic advances in tuberculosis
Year: 2009

Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB)
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools
Year: 2012


Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015

Deficient in silico selection of mycobacterium tuberculosis (MTB) epitopes in tuberculosis (TB) patients
Source: Eur Respir J 2006; 28: Suppl. 50, 801s
Year: 2006

Mycobacterium tuberculosis (MTB) content in the air of in-patient facility for the management of pulmonary tuberculosis (TB)
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001

Peculiarities and results of treatment in XDR pulmonary tuberculosis (PTB)
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012

Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB)
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009